JP2023532753A5 - - Google Patents

Info

Publication number
JP2023532753A5
JP2023532753A5 JP2023500304A JP2023500304A JP2023532753A5 JP 2023532753 A5 JP2023532753 A5 JP 2023532753A5 JP 2023500304 A JP2023500304 A JP 2023500304A JP 2023500304 A JP2023500304 A JP 2023500304A JP 2023532753 A5 JP2023532753 A5 JP 2023532753A5
Authority
JP
Japan
Prior art keywords
administered
chimeric anti
patient
dinutuximab
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023500304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532753A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2021/051721 external-priority patent/WO2022008902A1/en
Publication of JP2023532753A publication Critical patent/JP2023532753A/ja
Publication of JP2023532753A5 publication Critical patent/JP2023532753A5/ja
Pending legal-status Critical Current

Links

JP2023500304A 2020-07-06 2021-07-06 Gd2陽性がんを治療するための方法 Pending JP2023532753A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305766 2020-07-06
EP20305766.6 2020-07-06
PCT/GB2021/051721 WO2022008902A1 (en) 2020-07-06 2021-07-06 Method for treating a gd2-positive cancer

Publications (2)

Publication Number Publication Date
JP2023532753A JP2023532753A (ja) 2023-07-31
JP2023532753A5 true JP2023532753A5 (cg-RX-API-DMAC7.html) 2024-07-10

Family

ID=71833285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500304A Pending JP2023532753A (ja) 2020-07-06 2021-07-06 Gd2陽性がんを治療するための方法

Country Status (11)

Country Link
US (1) US20230295339A1 (cg-RX-API-DMAC7.html)
EP (1) EP4175988A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023532753A (cg-RX-API-DMAC7.html)
KR (1) KR20230066320A (cg-RX-API-DMAC7.html)
CN (1) CN115835884A (cg-RX-API-DMAC7.html)
AU (1) AU2021303625A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022027125A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187938A1 (cg-RX-API-DMAC7.html)
IL (1) IL299504A (cg-RX-API-DMAC7.html)
MX (1) MX2023000384A (cg-RX-API-DMAC7.html)
WO (1) WO2022008902A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
EP4218811A1 (en) 2012-06-18 2023-08-02 Apeiron Biologics AG Method for treating a gd2 positive cancer
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
EA201691055A1 (ru) * 2013-11-21 2016-11-30 Апейрон Биолоджикс Аг Препараты и способы лечения gd2-положительного рака
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
CA3010981C (en) * 2016-01-11 2024-09-17 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

Similar Documents

Publication Publication Date Title
JP2020090507A5 (cg-RX-API-DMAC7.html)
JP2014500295A5 (cg-RX-API-DMAC7.html)
JP2001517705A5 (cg-RX-API-DMAC7.html)
JP2009539769A5 (cg-RX-API-DMAC7.html)
JP2014077003A5 (cg-RX-API-DMAC7.html)
JP2018528185A5 (cg-RX-API-DMAC7.html)
JP2020523356A5 (cg-RX-API-DMAC7.html)
Malpas et al. Rubidomycin in acute leukaemia in adults
JP2022527334A5 (cg-RX-API-DMAC7.html)
JP6656397B2 (ja) 抗腫瘍薬物の効果を有する併用薬物
JP2005525409A5 (cg-RX-API-DMAC7.html)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
CN117959315B (zh) 化合物pgg作为krasg12d抑制剂mrt1133的增效剂联合治疗胰腺癌的应用
Ward et al. Pacemaker related infective endocarditis from Staphylococcus lugdunensis: a case report
JP2020524164A5 (cg-RX-API-DMAC7.html)
CN101588800B (zh) 给药抗肿瘤化合物的方法
South-East European Oncology Group (SEEOG) et al. Phase II study of 4′-epi-doxorubicin in patients with untreated, extensive small cell lung cancer
CN105769882B (zh) 一种抑制血栓形成的药物组合物及其用途
Miyata et al. Fatal pulmonary veno-occlusive disease after chemotherapy for Burkitt's lymphoma.
Lakhdhir et al. Beyond the pleasure principle-fatal cardiac arrhythmias after ingestion of an herbal medication
Brack et al. Application for the Inclusion of Vinorelbine for the Treatment of Rhabdomyosarcoma as first line treatment on the WHO Essential Medicines List for Children 2021
Loehrer Sr et al. Extensive small cell lung cancer: trials of Indiana University and the Hoosier Oncology Group
JP2026507878A5 (cg-RX-API-DMAC7.html)
JP2023182667A5 (cg-RX-API-DMAC7.html)
Gasparo et al. 333 Combined treatment of malignant pleural mesothelioma (MPM): Surgical resection and adjuvant chemotherapy